Milestones

MS10. Establishments of the protocol for super resolution imaging in cells (IBEC). Month 18.
Means of verification: Image resolution analysis.

MS16. Synthesis and evaluation of the first cell-targeted nanocarrier (TUE). Month 24.
Means of verification: Cell targeting experiments.

MS19. Toxicity and delivery screening in a 3D cancer model (BGX). Month 32.
Means of verification: Biological assays.

MS20. Anticancer activity of the nanocatalysts against melanoma, breast and prostate cancer (TAU). Month 36.
Means of verification: In vivo assays.

 

MILESTONES COMPLETED

MS1. Guidelines for recruitment and assessment of ESRs, PCDPs, strategy for dealing with scientific misconduct (IBEC). Month 4. – COMPLETED 21/08/18
Means of verification: Guidelines available to all partners and approved by SB.

MS2. Assessment Commissions (IBEC). Month 6. – COMPLETED 01/09/18
Means of verification: AC designated and operative.

MS3. Intranet and extranet website (EDI). Month 6. – COMPLETED 12/09/18
Means of verification: Tool completed and functional.

MS4. ESRs Recruitment and PCDPs (IBEC). Month 12. – COMPLETED 28/01/20
Means of verification: Employment contracts and agreement on the strategy for dealing with scientific misconduct properly signed and PCDPs ready for all ESRs.

MS5. ESR local doctoral studies (IBEC). Month 12. – COMPLETED 15/09/19
Means of verification: All ESRs accepted and enrolled in the corresponding doctoral programme.

MS6. Project Check (IBEC). Month 14. – COMPLETED 05/06/19
Means of verification: Meeting between REA and consortium.

MS7. Synthesis of the first prodye (IBEC). Month 18. – COMPLETED 17/05/19
Means of verification: Spectroscopic characterization.

MS8. Synthesis of the first catalyst (GRO). Month 18. – COMPLETED 30/09/19
Means of verification: Spectroscopic characterization and activity test.

MS9. Synthesis of the first prodrug (EDI). Month 18. – COMPLETED 27/06/19
Means of verification: Spectroscopic characterization.

MS11. Establishments of the protocol for in vivo cancer imaging (TAG). Month 18. – COMPLETED 01/02/20
Means of verification: Image analysis.

MS12. First catalyst supported on a nanoparticle (TUE). Month 21. – COMPLETED 30/06/19
Means of verification: Spectroscopic characterization.

MS13. Establishment of an mCherry orthotopic cancer model (TAU). Month 21. – COMPLETED 16/09/19
Means of verification: Histology.

MS14. Midterm project assessment (IBEC). Month 24. – COMPLETED 03/02/20
Means of verification: Project follows as planned.

MS15. Midterm dissemination and outreach activities assessment (TAU). Month 24. – COMPLETED 03/02/20
Means of verification: Number and quality of publications, conferences attended, outreach activities conducted.

MS17. Achievement of a library of prodrugs for several cancer types (EDI). Month 28. – COMPLETED 05/10/20
Means of verification: Spectroscopic characterization.

MS18. A library of supported catalysts fully characterized and ranked in efficiency (EDI). Month 30. – COMPLETED 18/12/20
Means of verification: Spectroscopic characterization.